Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats

Menopause

Volumn 17, Issue 1, 2010, Pages 127-134

  Chung, Ming Ting ^a   Cheng, Pao Yun ^b   Lam, Kwok Keung ^c,d   Chen, Shu Ying ^e   Ting, Yi Fan ^f   Yen, Mao Hsiung ^f   Lee, Yen Mei ^f  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Catholic Mercy Hospital Hsinchu   (Taiwan)

^e HUNGKUANG UNIVERSITY   (Taiwan)

^f NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Apoptosis; Arrhythmias; Estrogen; Myocardial ischemia reperfusion injury; Nuclear factor JB; Ovariectomy; Raloxifene

Indexed keywords

CASPASE 3; CREATINE KINASE MB; ESTRADIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; MYELOPEROXIDASE; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE TACHYCARDIA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OVARIECTOMY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; OVARIECTOMY; POSTMENOPAUSE; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TACHYCARDIA, VENTRICULAR; TIME;

EID: 74549197632     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181b4c4ac     Document Type: Article

References (41)

1. Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasmin-ogen activator in acute myocardial infarction. Stent Versus Thrombol-ysis for Occluded Coronary Arteries in Patients With Acute Myocardial Infarction Study Investigators. N Engl J Med 2000;343:385-391.
2. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903. (Pubitemid 32553358)
3. Cannon RO 3rd. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2005;2:88-94.
4. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myo-cardial ischemiaVreperfusion injury. Cardiovasc Res 1999;43:860-878.
5. Kis A, Yellon DM, Baxter GF. Role of nuclear factor-JB activation in acute ischaemia-reperfusion injury in myocardium. Br J Pharmacol 2003;138:894-900.
6. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element Bdecoy[ against nuclear factor-JB binding site prevents myo-cardial infarction. Nat Med 1997;3:894-899.
7. Carlson DL, White DJ, Maass DL, Nguyen RC, Giroir B, Horton JW. IJB overexpression in cardiomyocytes prevents NF-JB translocation and provides cardioprotection in trauma. Am J Physiol Heart Circ Physiol 2003;284:H804-H814.
8. Pye J, Ardeshirpour F, McCain A, et al. Proteasome inhibition ablates activation of NF-JB in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 2003;284:H919-H926.
9. Krijnen PA, Nijmeijer R, Meijer CJ, Visser CA, Hack CE, Niessen HW. Apoptosis in myocardial ischemia and infarction. J Clin Pathol 2002; 55:801-811.
10. Hale SL, Birnbaum Y, Kloner RA. A-Estradiol, but not -estradiol, reduced myocardial necrosis in rabbits after ischemia and reperfusion. Am Heart J 1996;132:258-262.
11. Booth EA, Marchesi M, Kilbourne EJ, Lucchesi BR. 17A-Estradiol as a receptor-mediated cardioprotective agent. J Pharmacol Exp Ther 2003; 307:395-401.
12. McHugh NA, Cook SM, Schairer JL, Bidgoli MM, Merrill GF. Ischemia-and reperfusion-induced ventricular arrhythmias in dogs: effects of estrogen. Am J Physiol 1995;268:H2569-H2573.
13. Tsai CH, Su SF, Chou TF, Lee TM. Differential effects of sarcolemmal and mitochondrial KATP channels activated by 17A-estradiol on reper-fusion arrhythmias and infarct size in canine hearts. J Pharmacol Exp Ther 2002;301:234-240.
14. Booth EA, Lucchesi BR. Estrogen-mediated protection in myocardial ischemia-reperfusion injury. Cardiovasc Toxicol 2008;8:101-113.
15. Riggs BL, Hartmann LC. Selective estrogen-receptor modulatorsV mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-629.
16. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-1524.
17. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 2007;8:229-239.
18. Ogita H, Node K, Asanuma H, et al. Amelioration of ischemia-and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J Am Coll Cardiol 2002;40: 998-1005.
19. Nemcsik J, Morschl E, Egresits J, et al. Raloxifene lowers ischemia susceptibility by increasing nitric oxide generation in the heart of ovari-ectomized rats in vivo. Eur J Pharmacol 2004;495:179-184.
20. Viereck V, Grundker C, Blaschke S, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 2003;88:4206-4213.
21. Esposito E, Iacono A, Raso GM, et al. Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. Endocrinology 2005;146: 3301-3308.
22. Lee YM, Cheng PY, Hong SF, et al. Oxidative stress induces vascular heme oxygenase-1 expression in ovariectomized rats. Free Radic Biol Med 2005;39:108-117.
23. Chen SY, Hsiao G, Hwang HR, Cheng PY, Lee YM. Tetramethylpyra-zine induces heme oxygenase-1 expression and attenuates myocardial ischemia/reperfusion injury in rats. J Biomed Sci 2006;13:731-740.
24. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications. Circulation 2001;104: 2981-2989.
25. Weyrich AS, Ma XL, Lefer AM. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation 1992;86:279-288.
26. Ek RO, Yildiz Y, Cecen S, Yenisey C, Kavak T. Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats. Mol Cell Biochem 2008;308:227-235.
27. Pavo I, Laszlo F, Morschl E, et al. Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasocon-striction in ovariectomized rats. Eur J Pharmacol 2000;410:101-104.
28. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in is-chemic cerebrovascular disease. Stroke 2002;33:2115-2122.
29. Sbarouni E, Flevari P, Kroupis C, Kyriakides ZS, Koniavitou K, Kremastinos DT. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther 2003;17:319-323.
30. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endo-thelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003;88:2135-2140.
31. Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-JB signaling in heart. J Mol Cell Cardiol 2006;41:580-591.
32. Squadrito F, Deodato B, Squadrito G, et al. Gene transfer of IJB limits infarct size in a mouse model of myocardial ischemia-reperfusion injury. Lab Invest 2003;83:1097-1104.
33. Moss NC, Stansfield WE, Willis MS, Tang R, Selzman CH. IKKA inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007;293: H2248-H2253.
34. Fan H, Sun B, Gu Q, Lafond-Walker A, Cao S, Becker LC. Oxygen radicals trigger activation of NFJB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol 2002;282:H1778-H1786.
35. Honda HM, Korge P, Weiss JN. Mitochondria and ischemia/reperfusion injury. Ann N Y Acad Sci 2005;1047:248-258.
36. Logue SE, Gustaffson AB, Samali A, Gottlieb RA. Ischemia/reperfusion injury at the intersection with cell death. J Mol Cell Cardiol 2005;38: 21-33.
37. Klinge CM. Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem 2008;105:1342-1351.
38. Razmara A, Sunday L, Stirone C, et al. Mitochondrial effects of estrogen are mediated by estrogen receptor > in brain endothelial cells. J Pharmacol Exp Ther 2008;325:782-790.
39. Mann V, Huber C, Kogianni G, Collins F, Noble B. The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007;40:674-684.
40. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apo-ptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004;24:1309-1314.
41. Liu HR, Tao L, Gao E, et al. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulationVa novel mechanism for the car-dioprotective effects of PPAR agonists. Cardiovasc Res 2009;81:344-352.